Genome editing for scalable production of alloantigen‐free lentiviral vectors for in vivo gene therapy

Genome editing for scalable production of alloantigen‐free lentiviral vectors for in vivo gene therapy

Abstract Lentiviral vectors (LV) are powerful and versatile vehicles for gene therapy. However, their complex biological composition challenges large‐scale manufacturing and raises concerns for in vivo applications, because particle components and contaminants may trigger immune responses. Here, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Michela Milani, Andrea Annoni, Sara Bartolaccini, Mauro Biffi, Fabio Russo, Tiziano Di Tomaso, Andrea Raimondi, Johannes Lengler, Michael C Holmes, Friedrich Scheiflinger, Angelo Lombardo, Alessio Cantore, Luigi Naldini
Format: Article
Language:English
Published: Springer Nature 2017-08-01
Series:EMBO Molecular Medicine
Subjects:
gene therapy
hemophilia
lentiviral vectors
MHC‐I
stable producer cell line
Online Access:https://doi.org/10.15252/emmm.201708148
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201708148

Similar Items